← United States · Coverage record
US · SEC FORM 4
SELLAS Life Sciences Group, Inc.
SLS · Nasdaq · CIK 0001390478 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
1 Form 4 transaction lines observed in the same window
0 sales · 1 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-11-19 · Kalin Katherine Bach.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 55,128,974
- Previous report
- 59,068,630
- Avg daily volume
- 5,836,430
- Days to cover
- 9.4
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-11-19 | Kalin Katherine Bach | Purchase (P) | Common Stock | 63,400 | USD 1.59 | USD 100,806 | SEC filing ↗ |
| 2025-06-12 | VAN NOSTRAND ROBERT L | Purchase (P) | Common Stock | 10,000 | USD 1.48 | USD 14,800 | SEC filing ↗ |
| 2025-05-30 | Wasman Jane | Purchase (P) | Common Stock | 20,000 | USD 1.69 | USD 33,800 | SEC filing ↗ |
| 2025-05-22 | Kalin Katherine Bach | Purchase (P) | Common Stock | 20,000 | USD 1.80 | USD 36,000 | SEC filing ↗ |
Form 4 evidence
12 transaction lines in the latest 365-day window; 70 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-16 | Stergiou Angelos M. | Award / grant (A) | Common Stock | 1,065,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-07 | Wasman Jane | Award / grant (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-07 | Varian John | Award / grant (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
Show recent Form 4 evidence (12 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-16 | Stergiou Angelos M. | Award / grant (A) | Common Stock | 1,065,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-07 | Wasman Jane | Award / grant (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-07 | Varian John | Award / grant (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-07 | VAN NOSTRAND ROBERT L | Award / grant (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-07 | SCHEINBERG DAVID A | Award / grant (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-07 | Kalin Katherine Bach | Award / grant (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-07 | CICIC DRAGAN | Award / grant (A) | Common Stock | 300,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-07 | Burns John Thomas | Award / grant (A) | Common Stock | 300,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-03 | Stergiou Angelos M. | J (J) | Common Stock | 187,066 | USD 1.50 | USD 280,599 | SEC filing ↗ |
| 2025-12-03 | CICIC DRAGAN | J (J) | Common Stock | 63,800 | USD 1.50 | USD 95,700 | SEC filing ↗ |
| 2025-12-03 | Burns John Thomas | J (J) | Common Stock | 58,592 | USD 1.50 | USD 87,888 | SEC filing ↗ |
| 2025-11-19 | Kalin Katherine Bach | Purchase (P) | Common Stock | 63,400 | USD 1.59 | USD 100,806 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-19 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | SLS |
| CIK | 0001390478 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 70 transaction lines from 2020-03-12 to 2026-06-16 4 P purchase lines · 6 S sale lines · 60 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.